Idioma:

3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis

Helfenstein, Seth ; Riesterer, Oliver ; Meier, Urs R ; Papachristofilou, Alexandros ; Kasenda, Benjamin ; Pless, Miklos ; Rothschild, Sacha I

Radiation oncology (London, England), 2019-02, Vol.14 (1), p.32-10, Article 32 [Revista revisada por pares]

England: BioMed Central Ltd

Texto completo disponible

Citas Citado por

Acciones

Título:
3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis
Autor: Helfenstein, Seth ; Riesterer, Oliver ; Meier, Urs R ; Papachristofilou, Alexandros ; Kasenda, Benjamin ; Pless, Miklos ; Rothschild, Sacha I
Materias: Analysis ; Antineoplastic agents ; Cancer ; Cancer therapies ; Carcinoma ; Care and treatment ; Chemo-radiotherapy ; Chemoradiotherapy ; Chemotherapy ; Cisplatin ; Confidence intervals ; Dosage ; Dose ; Dose-response relationship ; Head & neck cancer ; Head and neck cancer ; Head and neck squamous carcinoma ; Hospitals ; Laboratories ; Medical prognosis ; Neck ; NMR ; Nuclear magnetic resonance ; Outcome and process assessment (Medical care) ; Patients ; Prognosis ; Radiation therapy ; Radiotherapy ; Schedules ; Squamous cell carcinoma ; Tomography ; Toxicity ; Treatment
Es parte de: Radiation oncology (London, England), 2019-02, Vol.14 (1), p.32-10, Article 32
Descripción: Concurrent chemoradiotherapy with cisplatin is standard for patients (pts) with loco-regionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) and for patients with resected SCCHN with high-risk features. The standard regimen includes 3-weekly cisplatin, but weekly regimens are often used to lower toxicity. Reaching a cumulative dose of ≥200 mg/m cisplatin was shown being associated with improved outcome. We herein investigated cumulative dose reached and toxicities between the 3-weekly and weekly cisplatin regimens with concurrent radiotherapy. Multicentre, retrospective analysis of all patients undergoing combined RCT with cisplatin treated at 3 centres in Switzerland between 06/2008 and 12/2015. Three hundred fourteen pts. were included (3-weekly, N = 127; weekly, N = 187). Median cumulative cisplatin dose was 200 mg/m (IQR 150-300) for pts. treated with a 3-weekly schedule and 160 mg/m (120-240) for the weekly schedule, consequently more pts. treated with a 3-weekly schedule reached a cumulative dose ≥200 mg/m (75.6% vs. 47.1%, p < 0.001). This association was also observed in multivariable analysis adjusted for age and sex (OR 3.46, 95% confidence interval [CI], 2.1-5.7). The 3-weekly regimen led to a higher rate of acute renal toxicity (33.1% vs. 20.9%, p = 0.022). In the landmark analysis, we could not confirm that a cisplatin dose ≥200 mg/m is associated with better survival (HR 1.3, 95% CI 0.8-1.9). Significantly more patients receive a cumulative cisplatin dose of ≥200 mg/m , when treated with a 3-weekly schedule compared to weekly dosing. The previously reported association between a cumulative cisplatin dose ≥200 mg/m and improved outcome could not be shown in our study.
Editor: England: BioMed Central Ltd
Idioma: Inglés

Enlaces

View this record in MEDLINE/PubMed

Volver a la lista de resultados

Anterior Resultado 4 Siguiente Ir a la siguiente página

Realización: Logos de Redes Sociales:

3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis

Helfenstein, Seth ; Riesterer, Oliver ; Meier, Urs R ; Papachristofilou, Alexandros ; Kasenda, Benjamin ; Pless, Miklos ; Rothschild, Sacha I

England: BioMed Central Ltd

Buscando en bases de datos remotas, por favor espere